Bright Minds Biosciences Proprietary Compound Shows Reduction Of Seizures In Pre-Clinical Studies

Bright Minds Biosciences (CSE: DRUG) this morning announced preliminary results from an ongoing study being conducted by the firm. The company has seen efficacy in rodent models of Dravet Syndrome, a form of epilepsy, within ongoing late pre-clinical trials.

The efficacy was seen in what the company refers to as its 5-HT2C agonist, BMB-101. The compound is referred to as a novel, well-characterized highly selective agonist, which was originally developed by the firms Chief Scientific Officer.

“These early positive results around the antiseizure effects of BMB-101 and other analogues are very encouraging and further reinforce the potential of serotonin (5-HT2C) agonists to address difficult to treat developmental and genetic epilepsies, including Dravet Syndrome and Lennox-Gastaut Syndrome (“LGS”),” said Ian McDonald on the results, whom is CEO of the firm.

The compound itself was studied in three separate models as part of the firms pre-clinical study. The first study, referred to as a Scn1Lab zebrafish model, reportedly mimics clinical hallmarks of Dravet syndrome, with similar experiments using the model shown to have successfully predicted the clinical efficacy of drugs against the syndrome.

In layman terms, other models conducted by the firm demonstrated a 74% decrease in seizure duration one hour after injection of the compound into rodents, while a “significant number” of the subjects were reportedly completely protected from seizures. Further, at the highest dosage administered, all rats were protected from seizures administered via the maximum electroshock seizure model, which proves promising for the firms proprietary compound.

“BMB-101 is a promising lead candidate to treat Dravet Syndrome patients. The data provide clear evidence that it has a therapeutic effect on the abnormal brain activity of Scn1Lab zebrafish, resulting in pronounced antiseizure activity. The effects of BMB-101 parallel those of other anti-epileptics, such as fenfluramine, a drug marketed for these patients.”

Ian McDonald, CEO

Bright Minds Biosciences last traded at $6.42 on the CSE.

FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply